Who are IMU-838 tablets's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Leflunomide(LEF), Leflunomide 10 milligram (MG).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/imu-838-tablets.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

IMU-838 tablets — Competitive Intelligence Brief

IMU-838 tablets (IMU-838 tablets) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: DHODH inhibitor. Area: Immunology.

phase 3 DHODH inhibitor Dihydroorotate dehydrogenase (DHODH) Immunology Small molecule Live · refreshed every 30 min

Target snapshot

IMU-838 tablets (IMU-838 tablets) — Immunic AG. IMU-838 is a selective immunomodulator that inhibits dihydroorotate dehydrogenase (DHODH) to reduce proliferation of activated lymphocytes while preserving regulatory T cells.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
IMU-838 tablets TARGET	IMU-838 tablets	Immunic AG	phase 3	DHODH inhibitor	Dihydroorotate dehydrogenase (DHODH)
Leflunomide(LEF)	Leflunomide(LEF)	Nanjing Children's Hospital	marketed	Immunosuppressant; DHODH inhibitor	Dihydroorotate dehydrogenase (DHODH)
Leflunomide 10 milligram (MG)	Leflunomide 10 milligram (MG)	P. Verschueren	marketed	DHODH inhibitor; disease-modifying antirheumatic drug (DMARD)	Dihydroorotate dehydrogenase (DHODH)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (DHODH inhibitor class)

Immunic AG · 1 drug in this class
Medicines for Malaria Venture · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). IMU-838 tablets — Competitive Intelligence Brief. https://druglandscape.com/ci/imu-838-tablets. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab